123 related articles for article (PubMed ID: 17324825)
1. Distribution to the skin of epinastine hydrochloride in atopic dermatitis patients.
Toyoda M; Nakamura M; Nakagawa H
Eur J Dermatol; 2007; 17(1):33-6. PubMed ID: 17324825
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children.
Sarashina A; Tatami S; Yamamura N; Tsuda Y; Igarashi T
Br J Clin Pharmacol; 2005 Jan; 59(1):43-53. PubMed ID: 15606439
[TBL] [Abstract][Full Text] [Related]
3. Dermal objective pharmacodynamic profile of cetirizine and epinastine: two controlled, randomised, double-blind, crossover studies.
Leroy T; van Neste D
Int J Clin Pract; 2002 Oct; 56(8):568-73. PubMed ID: 12425364
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses.
Minami T; Ishida W; Kishimoto T; Nakajima I; Hino S; Arai R; Matsunaga T; Fukushima A; Yamagami S
PLoS One; 2019; 14(1):e0210362. PubMed ID: 30699147
[TBL] [Abstract][Full Text] [Related]
5. Epinastine 0.05% ophthalmic solution in contact lens-wearing subjects with a history of allergic conjunctivitis.
Nichols KK; Morris S; Gaddie IB; Evans D
Eye Contact Lens; 2009 Jan; 35(1):26-31. PubMed ID: 19125045
[TBL] [Abstract][Full Text] [Related]
6. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis.
Undre NA; Moloney FJ; Ahmadi S; Stevenson P; Murphy GM
Br J Dermatol; 2009 Mar; 160(3):665-9. PubMed ID: 19076975
[TBL] [Abstract][Full Text] [Related]
7. Quantitative determination of epinastine in plasma by high-performance liquid chromatography.
Ohtani H; Kotaki H; Sawada Y; Iga T
J Chromatogr B Biomed Appl; 1996 Aug; 683(2):281-4. PubMed ID: 8891928
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous measurement of epinastine and its metabolite, 9,13b-dehydroepinastine, in human plasma by a newly developed ultra-performance liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies.
Jeong SH; Jang JH; Cho HY; Lee YB
Biomed Chromatogr; 2020 Sep; 34(9):e4848. PubMed ID: 32302007
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of granulocytes in the lung and skin of guinea pigs. Inhibition by the anti-H1 antiallergic agent epinastine.
Fügner A; Meissner C
Arzneimittelforschung; 1994 Dec; 44(12):1338-42. PubMed ID: 7848354
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
[TBL] [Abstract][Full Text] [Related]
11. Contact and aeroallergens in adulthood atopic dermatitis.
Pónyai G; Hidvégi B; Németh I; Sas A; Temesvári E; Kárpáti S
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1346-55. PubMed ID: 18680530
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis.
Yamaguchi J; Aihara M; Kobayashi Y; Kambara T; Ikezawa Z
J Dermatol Sci; 2009 Jan; 53(1):48-54. PubMed ID: 18922683
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
[TBL] [Abstract][Full Text] [Related]
14. Are age-specific high serum IgE levels associated with worse symptomatology in children with atopic dermatitis?
Hon KL; Lam MC; Leung TF; Wong KY; Chow CM; Fok TF; Ng PC
Int J Dermatol; 2007 Dec; 46(12):1258-62. PubMed ID: 18173519
[TBL] [Abstract][Full Text] [Related]
15. Elestat (epinastine HCl ophthalmic solution 0.05%) as a therapeutic for allergic conjunctivitis.
Trattler WB; Luchs J; Majmudar P
Int Ophthalmol Clin; 2006; 46(4):87-99. PubMed ID: 17060795
[No Abstract] [Full Text] [Related]
16. Epinastine inhibits eosinophil chemotaxis and adhesion molecules in atopic dermatitis.
Matsukura M; Yajima A; Yamazaki F; Yudate T; Yamada H; Tezuka T
Skin Pharmacol Appl Skin Physiol; 2003; 16(6):405-10. PubMed ID: 14528065
[TBL] [Abstract][Full Text] [Related]
17. Effects of epinastine on the antitussive and rewarding effects of dihydrocodeine in mice.
Kamei J; Morita K; Ohsawa M; Onodera K
Methods Find Exp Clin Pharmacol; 1999 Dec; 21(10):663-8. PubMed ID: 10702962
[TBL] [Abstract][Full Text] [Related]
18. In vivo formation of prostaglandin E1 and prostaglandin E2 in atopic dermatitis.
Leonhardt A; Krauss M; Gieler U; Schweer H; Happle R; Seyberth HW
Br J Dermatol; 1997 Mar; 136(3):337-40. PubMed ID: 9115911
[TBL] [Abstract][Full Text] [Related]
19. Antihistamines and their role as antipruritics.
O'Donoghue M; Tharp MD
Dermatol Ther; 2005; 18(4):333-40. PubMed ID: 16297006
[TBL] [Abstract][Full Text] [Related]
20. Severity of disease, rather than xerosis, correlates with pruritus in patients with atopic dermatitis.
Hachisuka J; Takeuchi S; Kido M; Fukiwake N; Furue M
Int J Dermatol; 2009 Apr; 48(4):374-8. PubMed ID: 19335422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
